Symbols / ENGN $7.25 +0.28%
ENGN Chart
About
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 485.67M |
| Enterprise Value | 243.19M | Income | -122.44M | Sales | — |
| Book/sh | 4.20 | Cash/sh | 4.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 81 | IPO | — |
| P/E | — | Forward P/E | -3.85 | PEG | — |
| P/S | — | P/B | 1.72 | P/C | — |
| EV/EBITDA | -1.91 | EV/Sales | — | Quick Ratio | 11.36 |
| Current Ratio | 11.75 | Debt/Eq | 11.89 | LT Debt/Eq | — |
| EPS (ttm) | -2.29 | EPS next Y | -1.88 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-09 07:00 | ROA | -25.63% |
| ROE | -46.07% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 66.99M |
| Shs Float | 26.44M | Short Float | 2.37% | Short Ratio | 5.10 |
| Short Interest | — | 52W High | 12.25 | 52W Low | 2.65 |
| Beta | -0.28 | Avg Volume | 433.44K | Volume | 515.67K |
| Target Price | $23.36 | Recom | Strong_buy | Prev Close | $7.23 |
| Price | $7.25 | Change | 0.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$23.36
Mean price target
2. Current target
$7.25
Latest analyst target
3. DCF / Fair value
$-17.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.25
Low
$10.00
High
$30.00
Mean
$23.36
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Oppenheimer | Outperform → Outperform | $30 |
| 2026-03-09 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-11-12 | main | Morgan Stanley | Overweight → Overweight | $19 |
| 2025-11-12 | reit | Oppenheimer | Outperform → Outperform | $33 |
| 2025-11-12 | main | UBS | Neutral → Neutral | $10 |
| 2025-11-12 | main | Citizens | Market Outperform → Market Outperform | $21 |
| 2025-09-12 | main | Morgan Stanley | Overweight → Overweight | $18 |
| 2025-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-04-29 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2025-03-11 | main | Morgan Stanley | Overweight → Overweight | $34 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-18 | init | Piper Sandler | — → Overweight | $26 |
| 2025-02-14 | down | UBS | Buy → Neutral | $7 |
| 2024-12-23 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-12-23 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2024-12-06 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-11-27 | init | Raymond James | — → Outperform | $23 |
| 2024-11-18 | init | JMP Securities | — → Market Outperform | $18 |
| 2024-09-24 | reit | Oppenheimer | Outperform → Outperform | $30 |
- enGene Holdings: Key Catalysts Incoming For 2026 (NASDAQ:ENGN) - Seeking Alpha hu, 12 Mar 2026 22
- enGene (NASDAQ:ENGN) Upgraded to "Hold" at Wall Street Zen - MarketBeat Sat, 14 Mar 2026 06
- Experimental bladder cancer treatment from enGene aims for FDA review in 2026 - Stock Titan Mon, 09 Mar 2026 11
- HC Wainwright Reiterates 'Buy' Rating for enGene Holdings (ENGN) - GuruFocus Mon, 09 Mar 2026 16
- Engene stock price target lowered to $27 by Guggenheim on estimates - Investing.com ue, 10 Mar 2026 11
- ENGN Stock Price and Chart — NASDAQ:ENGN - TradingView ue, 23 Sep 2025 07
- Raymond James Maintains Strong Buy on ENGN enGene Holdings Inc March 2026 - Meyka ue, 10 Mar 2026 04
- Oppenheimer Maintains EnGene Holdings(ENGN.US) With Buy Rating, Cuts Target Price to $30 - 富途牛牛 Sun, 15 Mar 2026 04
- Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7% - MarketBeat Mon, 16 Mar 2026 22
- enGene (NASDAQ: ENGN) details Q1 loss, LEGEND trial data and cash runway - Stock Titan Mon, 09 Mar 2026 11
- enGene Holdings: Still A Buy After A Massive Surge (ENGN) - Seeking Alpha Wed, 12 Nov 2025 08
- Braidwell LP Invests $15.48 Million in enGene Holdings Inc. $ENGN - MarketBeat Sun, 15 Mar 2026 09
- Biotech enGene secures $125M to advance bladder cancer treatment detalimogene - Stock Titan ue, 20 Jan 2026 08
- enGene Holdings Inc. $ENGN Stock Position Lowered by Blue Owl Capital Holdings LP - MarketBeat Sat, 07 Mar 2026 08
- Hear enGene’s CEO in a live biotech fireside chat on Feb. 11 - Stock Titan Wed, 04 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 561797 | 4999993 | — | Purchase at price 8.90 per share. | FORBION GROWTH OPPORTUNITIES FUND I COOPERATIEF UA | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-30 00:00:00 | I |
| 1 | 470633 | 3012674 | — | Purchase at price 5.94 - 9.09 per share. | FORBION GROWTH OPPORTUNITIES FUND I COOPERATIEF UA | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-08 00:00:00 | D |
| 2 | 10000 | 57000 | — | Purchase at price 5.70 per share. | COOPER RONALD HAROLD WILFRED | Chief Executive Officer | — | 2024-09-27 00:00:00 | D |
| 3 | 120 | 107 | — | Conversion of Exercise of derivative security at price 0.89 per share. | GLICKMAN RICHARD M | Director | — | 2024-05-28 00:00:00 | D |
| 4 | 52529 | 787981 | — | Sale at price 15.00 - 15.01 per share. | FONDS DE SOLIDARITE DES TRAVAILLEURS DU | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-22 00:00:00 | D |
Financials
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -109.80 | -5.47M | -801.24K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.40 | 0.26 |
| NormalizedEBITDA | -113.80M | -51.67M | -81.11M | -19.72M |
| TotalUnusualItems | 0.00 | -366.00K | -13.66M | -3.06M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -366.00K | -13.66M | -3.06M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -117.30M | -55.14M | -99.92M | -24.46M |
| ReconciledDepreciation | 509.00K | 323.00K | 175.00K | 238.00K |
| EBITDA | -113.80M | -52.04M | -94.77M | -22.78M |
| EBIT | -114.31M | -52.36M | -94.95M | -23.02M |
| NetInterestIncome | 6.43M | 7.62M | -3.84M | -1.29M |
| InterestExpense | 2.99M | 2.80M | 4.95M | 1.42M |
| InterestIncome | 9.43M | 10.41M | 1.12M | 129.00K |
| NormalizedIncome | -117.30M | -54.78M | -91.72M | -22.21M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -117.30M | -55.14M | -99.92M | -24.46M |
| TotalExpenses | 123.17M | 62.30M | 26.06M | 19.43M |
| TotalOperatingIncomeAsReported | -123.17M | -62.30M | -26.06M | -19.43M |
| DilutedAverageShares | 37.78M | 23.20M | 23.20M | 23.20M |
| BasicAverageShares | 37.78M | 23.20M | 23.20M | 23.20M |
| DilutedEPS | -1.46 | -4.52 | -1.25 | -0.96 |
| BasicEPS | -1.46 | -4.52 | -1.25 | -0.96 |
| DilutedNIAvailtoComStockholders | -117.30M | -55.14M | -104.74M | -29.02M |
| NetIncomeCommonStockholders | -117.30M | -55.14M | -104.74M | -29.02M |
| OtherunderPreferredStockDividend | 0.00 | -2.82M | ||
| PreferredStockDividends | 4.82M | 4.56M | 1.63M | |
| NetIncome | -117.30M | -55.14M | -99.92M | -24.46M |
| NetIncomeIncludingNoncontrollingInterests | -117.30M | -55.14M | -99.92M | -24.46M |
| NetIncomeContinuousOperations | -117.30M | -55.14M | -99.92M | -24.46M |
| TaxProvision | 0.00 | -19.00K | 17.00K | 22.00K |
| PretaxIncome | -117.30M | -55.16M | -99.90M | -24.44M |
| OtherIncomeExpense | -569.00K | -479.00K | -70.00M | -3.72M |
| OtherNonOperatingIncomeExpenses | -569.00K | -113.00K | -56.34M | -662.00K |
| SpecialIncomeCharges | 0.00 | -366.00K | -3.09M | 0.00 |
| OtherSpecialCharges | 366.00K | 3.09M | -1.73M | |
| GainOnSaleOfSecurity | -10.57M | -3.06M | -4.18M | |
| NetNonOperatingInterestIncomeExpense | 6.43M | 7.62M | -3.84M | -1.29M |
| InterestExpenseNonOperating | 2.99M | 2.80M | 4.95M | 1.42M |
| InterestIncomeNonOperating | 9.43M | 10.41M | 1.12M | 129.00K |
| OperatingIncome | -123.17M | -62.30M | -26.06M | -19.43M |
| OperatingExpense | 123.17M | 62.30M | 26.06M | 19.43M |
| OtherOperatingExpenses | 1.88M | 1.13M | 700.00K | 253.00K |
| ResearchAndDevelopment | 94.48M | 38.31M | 16.46M | 15.47M |
| SellingGeneralAndAdministration | 28.68M | 23.98M | 8.47M | 3.26M |
| GeneralAndAdministrativeExpense | 28.68M | 23.98M | 8.47M | 3.26M |
| OtherGandA | 11.47M | 11.95M | 3.69M | 1.21M |
| SalariesAndWages | 17.21M | 12.03M | 4.78M | 2.06M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 52.02M | 50.98M | 23.20M | 23.20M |
| ShareIssued | 52.02M | 50.98M | 23.20M | 23.20M |
| NetDebt | 11.68M | |||
| TotalDebt | 31.80M | 25.02M | 9.78M | 32.11M |
| TangibleBookValue | 167.71M | 272.61M | 72.49M | -76.61M |
| InvestedCapital | 191.04M | 295.78M | 82.26M | -44.50M |
| WorkingCapital | 169.41M | 232.70M | 80.18M | 17.48M |
| NetTangibleAssets | 167.71M | 272.61M | 72.49M | -23.50M |
| CapitalLeaseObligations | 8.47M | 1.85M | 0.00 | 0.00 |
| CommonStockEquity | 167.71M | 272.61M | 72.49M | -76.61M |
| PreferredStockEquity | 53.12M | 53.12M | ||
| TotalCapitalization | 183.03M | 295.08M | 81.70M | 7.35M |
| TotalEquityGrossMinorityInterest | 167.71M | 272.61M | 72.49M | -23.50M |
| StockholdersEquity | 167.71M | 272.61M | 72.49M | -23.50M |
| GainsLossesNotAffectingRetainedEarnings | -888.00K | -1.42M | -1.02M | -1.02M |
| OtherEquityAdjustments | -888.00K | -1.42M | -1.02M | -1.02M |
| RetainedEarnings | -372.03M | -254.73M | -199.59M | -99.67M |
| AdditionalPaidInCapital | 27.35M | 18.95M | 13.72M | 7.68M |
| CapitalStock | 513.28M | 509.81M | 259.37M | 69.51M |
| CommonStock | 513.28M | 509.81M | 259.37M | 16.39M |
| PreferredStock | 0.00 | 53.12M | 53.12M | |
| TotalLiabilitiesNetMinorityInterest | 53.76M | 38.56M | 14.47M | 47.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.78M | 23.90M | 9.22M | 42.30M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 53.12M | 53.12M | |
| DerivativeProductLiabilities | 0.00 | 11.46M | 9.09M | |
| LongTermDebtAndCapitalLeaseObligation | 21.78M | 23.90M | 9.22M | 30.84M |
| LongTermCapitalLeaseObligation | 6.46M | 1.43M | 0.00 | |
| LongTermDebt | 15.32M | 22.47M | 9.22M | 30.84M |
| CurrentLiabilities | 31.98M | 14.66M | 5.26M | 5.10M |
| OtherCurrentLiabilities | 577.00K | 225.00K | 113.00K | 21.00K |
| CurrentDebtAndCapitalLeaseObligation | 10.02M | 1.12M | 562.00K | 1.26M |
| CurrentCapitalLeaseObligation | 2.01M | 423.00K | 0.00 | 0.00 |
| CurrentDebt | 8.00M | 699.00K | 562.00K | 1.26M |
| OtherCurrentBorrowings | 8.00M | 699.00K | 562.00K | 1.26M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.05M | 3.48M | 814.00K | 676.00K |
| PayablesAndAccruedExpenses | 17.33M | 9.84M | 3.77M | 3.16M |
| CurrentAccruedExpenses | 10.63M | 8.43M | 2.57M | 2.42M |
| Payables | 6.71M | 1.41M | 1.20M | 745.00K |
| TotalTaxPayable | 19.00K | 0.00 | 39.00K | 22.00K |
| IncomeTaxPayable | 19.00K | 0.00 | 39.00K | 22.00K |
| AccountsPayable | 6.69M | 1.41M | 1.16M | 723.00K |
| TotalAssets | 221.47M | 311.17M | 86.96M | 23.91M |
| TotalNonCurrentAssets | 20.08M | 63.81M | 1.52M | 1.33M |
| OtherNonCurrentAssets | 1.36M | 1.37M | 930.00K | 939.00K |
| InvestmentsAndAdvances | 8.52M | 59.53M | 0.00 | |
| InvestmentinFinancialAssets | 8.52M | 59.53M | 0.00 | |
| AvailableForSaleSecurities | 8.52M | 59.53M | ||
| NetPPE | 10.19M | 2.91M | 589.00K | 387.00K |
| AccumulatedDepreciation | -2.10M | -1.61M | -1.73M | -1.55M |
| GrossPPE | 12.30M | 4.52M | 2.32M | 1.94M |
| Leases | 262.00K | 239.00K | 129.00K | 122.00K |
| OtherProperties | 3.13M | 2.19M | 1.78M | 1.47M |
| MachineryFurnitureEquipment | 1.18M | 349.00K | 408.00K | 346.00K |
| BuildingsAndImprovements | 7.72M | 1.74M | 0.00 | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 201.39M | 247.36M | 85.44M | 22.58M |
| OtherCurrentAssets | 6.65M | 8.63M | 1.50M | 739.00K |
| RestrictedCash | 79.00K | 72.00K | 76.00K | 74.00K |
| Receivables | 927.00K | 332.00K | 2.34M | 1.34M |
| TaxesReceivable | 927.00K | 332.00K | 2.34M | 1.34M |
| CashCashEquivalentsAndShortTermInvestments | 193.74M | 238.33M | 81.52M | 20.43M |
| OtherShortTermInvestments | 143.58M | 65.33M | 0.00 | |
| CashAndCashEquivalents | 50.15M | 173.00M | 81.52M | 20.43M |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| FreeCashFlow | -100.72M | -49.21M | -25.06M | -17.75M |
| RepaymentOfDebt | -699.00K | -9.45M | -4.73M | -1.01M |
| IssuanceOfDebt | 0.00 | 22.50M | 38.00M | 29.40M |
| IssuanceOfCapitalStock | 0.00 | 260.15M | 56.89M | 0.00 |
| CapitalExpenditure | -1.49M | -925.00K | -318.00K | -153.00K |
| InterestPaidSupplementalData | 2.29M | 1.93M | 1.40M | 615.00K |
| EndCashPosition | 50.15M | 173.00M | 81.52M | 20.43M |
| BeginningCashPosition | 173.00M | 81.52M | 20.43M | 11.02M |
| EffectOfExchangeRateChanges | 1.00K | 1.00K | 1.00K | -805.00K |
| ChangesInCash | -122.85M | 91.48M | 61.09M | 10.22M |
| FinancingCashFlow | 1.52M | 265.72M | 86.15M | 27.97M |
| CashFlowFromContinuingFinancingActivities | 1.52M | 265.72M | 86.15M | 27.97M |
| NetOtherFinancingCharges | -13.58M | -4.06M | -435.00K | -144.00K |
| ProceedsFromStockOptionExercised | 2.22M | 6.10M | 44.00K | 12.00K |
| NetPreferredStockIssuance | 0.00 | 15.59M | ||
| PreferredStockIssuance | 0.00 | 15.59M | ||
| NetCommonStockIssuance | 0.00 | 260.15M | 56.89M | 0.00 |
| CommonStockIssuance | 0.00 | 260.15M | 56.89M | 0.00 |
| NetIssuancePaymentsOfDebt | -699.00K | 13.05M | 33.27M | 28.39M |
| NetLongTermDebtIssuance | -699.00K | 13.05M | 33.27M | 28.39M |
| LongTermDebtPayments | -699.00K | -9.45M | -4.73M | -1.01M |
| LongTermDebtIssuance | 0.00 | 22.50M | 38.00M | 29.40M |
| InvestingCashFlow | -25.14M | -125.95M | -318.00K | -153.00K |
| CashFlowFromContinuingInvestingActivities | -25.14M | -125.95M | -318.00K | -153.00K |
| NetInvestmentPurchaseAndSale | -23.65M | -125.03M | 0.00 | |
| SaleOfInvestment | 137.19M | 0.00 | ||
| PurchaseOfInvestment | -160.84M | -125.03M | 0.00 | |
| NetPPEPurchaseAndSale | -1.49M | -925.00K | -318.00K | -153.00K |
| SaleOfPPE | 0.00 | 1.00K | ||
| PurchaseOfPPE | -1.49M | -925.00K | -318.00K | -153.00K |
| OperatingCashFlow | -99.24M | -48.28M | -24.74M | -17.59M |
| CashFlowFromContinuingOperatingActivities | -99.24M | -48.28M | -24.74M | -17.59M |
| ChangeInWorkingCapital | 9.74M | 95.00K | -517.00K | 2.17M |
| ChangeInOtherCurrentLiabilities | 274.00K | -49.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 8.07M | 5.70M | 1.24M | 2.14M |
| ChangeInAccruedExpense | 3.13M | 5.22M | 868.00K | 2.34M |
| ChangeInPayable | 4.94M | 474.00K | 373.00K | -197.00K |
| ChangeInAccountPayable | 4.94M | 474.00K | 373.00K | -197.00K |
| ChangeInPrepaidAssets | 1.99M | -7.57M | -751.00K | -113.00K |
| ChangeInReceivables | -595.00K | 2.01M | -1.01M | 143.00K |
| OtherNonCashItems | 1.23M | 969.00K | 1.70M | 639.00K |
| StockBasedCompensation | 9.65M | 5.32M | 3.45M | 116.00K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 56.21M | 0.00 | |
| AmortizationOfSecurities | -3.07M | -232.00K | 0.00 | |
| DepreciationAmortizationDepletion | 509.00K | 323.00K | 175.00K | 238.00K |
| DepreciationAndAmortization | 509.00K | 323.00K | 175.00K | 238.00K |
| Depreciation | 509.00K | 323.00K | 175.00K | 238.00K |
| OperatingGainsLosses | 3.00K | 382.00K | 14.15M | 3.70M |
| GainLossOnInvestmentSecurities | 10.57M | 3.06M | 4.18M | |
| NetForeignCurrencyExchangeGainLoss | 3.00K | -6.00K | 489.00K | 646.00K |
| GainLossOnSaleOfPPE | 0.00 | 22.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -117.30M | -55.14M | -99.92M | -24.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ENGN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|